Subject Index

Aldosterone, synthesis 43, 45
Androgen insensitivity syndrome
  androgen programming 34, 36
  androgen replacement therapy in
    males 155, 156
clinical trials and orphan drugs 245
epidemiology 258
fertility 94, 95
gonadectomy 191
GrApSIA
  annual meetings 141, 142
  family meetings 142
  formation 139, 140
  goals
    education 141
    links with professionals 141
    overview 140–142
  testimonials
    adolescent concerns 145
    age distribution 143
    denial stage 143, 144
    diagnosis response 143
    GrApSIA role 146, 147
    identity 144
    motherhood 146
    partner relationships 145, 146
    physician-patient relationship
     146
    sexual relationships 145
    social setting 146
imaging
  gonads 78, 80
  recommendations 79
  vagina and sex ducts 84
  patient organizations 252, 253
Androgen receptor
  androgen programming 32–36
  domain function 29, 30
  epigenetics 37, 46
  gene 28, 29
  genomic action 30–32
  knockout mouse studies 24
  mutation, see Androgen insensitivity
    syndrome
  structure 29, 30
Androgen replacement therapy, see Hormone
  replacement therapy
Anogenital difference
  masculinization programming window 22,
   23
  overview 19
Anti-Müllerian hormone
  fertility in defects 95
  testes development role 8, 9, 19
APOD, epigenetics in expression 36
Aromatase deficiency, fertility 96
ATRX, testes development role 10, 11
Bipotential genital ridge, see Gonad
  development
BLIMP1, germ cell development role 175
Brain
  neuroimaging
    computed tomography 64
    diffusion tensor imaging 69
    functional magnetic resonance
      imaging 66, 67
    magnetic resonance imaging 64, 65
    magnetic resonance spectroscopy 67,
      68
    overview 63, 64
    positron emission tomography 65, 66
    single photon emission computed
      tomography 65
sexual dimorphism
  disorders of sex development 72
  function 70, 71
  structure 69, 70

CBX2, bipotential genital ridge development role 4
Centers of expertise, see Rare disease
Chromatin immunoprecipitation sequencing 59, 60
Clitoroplasty, see Feminizing genitoplasty
Commission Expert Group on Rare Diseases 237
Committee for Medicinal Products for Human Use 239
Committee for Orphan Medicinal Products 239
Communication, see Physician-patient relationship
Computed tomography, neuroimaging principles 64
Congenital adrenal hyperplasia clinical trials and orphan drugs 244, 245
dexamethasone therapy 244, 249
epidemiology 258
feminizing surgery, see Feminizing genitoplasty
fertility by type 95, 96
gene mutations 293, 294
hydrocortisone replacement therapy challenges 162, 165
children 163, 164
cortisol natural secretory pattern 161
dosing 162, 163
historical perspective 161
monitoring 166, 167
overview 160, 161
prenatal therapy 165, 166
imaging
genitalia 84, 85
neoimaging findings 72
perineal ultrasound 83
recommendations 79
incidence 203
mineralocorticoid replacement therapy 167, 168
patient organizations 252, 253
Cortisol, natural secretory pattern 161
CYP11A1 deficiency, steroid measurement 40
Cystoscopy, gonad investigation 77
Cytochrome b5 deficiencies, fertility 93
Dehydroepiandrosterone, synthesis 43
11-Deoxycorticosterone, synthesis 43, 45, 167
Desert Hedgehog, testes development role 9, 10
Developing countries, disorders of sex development
  age of presentation 259
  challenges 264, 265
diagnostic test facilities 259–262
epidemiology 258, 259
gender assignment considerations 263
multidisciplinary team 262
parental support groups 265, 266
social stigmas and taboos 263, 264
Dexamethasone, congenital adrenal hyperplasia treatment 244, 249
Diffusion tensor imaging
  neuroimaging principles 69
  sexual dimorphism studies of brain 70, 71
Dihydrotestosterone
cream 261, 262
fertility in deficiency 94
replacement therapy 153–155
synthesis 43, 44, 94
DMRT1, testes development role 9
DSDlife 289
DSDnet 290
e-Consultation, see Electronic resources, disorders of sex development
e-Information, see Electronic resources, disorders of sex development
e-Learning, see Electronic resources, disorders of sex development
Electronic resources, disorders of sex development
e-consultation 274
e-information
  examples 276, 277
  mapping to user 278
  nomenclature 278, 279
  overview 274, 275
  quality development 280
  repurposing related information 279
  self-management importance 277
  shared enterprise 275, 277
e-learning
assessment 272, 273
clinical reasoning 270
clinicians 269, 270
European Society for Pediatric
Endocrinology portal 269, 270
requirements 270, 271
overview 268, 269
prospects 280–282
steps in development 280, 281
Emx2, bipotential genital ridge development
role 5
ENCODE project 59
EPIRARE 246
E-Rare 241
Estrogen replacement therapy, see Hormone
replacement therapy
EU-TAIN 290
EUROCAT 241, 242
EuroDSD 289
European Cooperation of Science and
Technology 290
European Organisation for Rare Diseases 238, 239
European Project for Rare Diseases National
Plans Development 238, 239, 241
European reference networks 243, 286, 287
European Union Committee of Experts on
Rare Diseases 237, 239, 242, 243, 284–286

Feminizing genitoplasty
congenital adrenal hyperplasia
clitoral surgery outcomes 205
vaginoplasty outcomes 205–207
timing
early surgery
anxiety avoidance 211
cosmesis 212, 213
maternal estrogens and wound
healing 212
patient preference 215
psychological trauma avoidance 212
urinary tract infection
prevention 211, 212
guidelines 216–219
late surgery
clitoral surgery 214, 216
goals 213, 214
repeat surgery 216
sexual function outcomes 215
vaginal surgery 215, 216
overview 207, 210, 211, 219, 220
Fertility, disorders of sex development
androgen excess 46,XX disorders of sex
development 95, 96
dysgenetic disorders of sex
development 88–91
overview 87, 88
testicular hormone 46,XY disorders of sex
development 92–95
α-Fetoprotein, germ cell cancer marker 193
Fludrocortisone, congenital adrenal
hyperplasia management 167, 168
FOG2, testes development role 7, 8
FOXL2, ovary development role 12, 13, 175
Functional magnetic resonance imaging
neuroimaging principles 66, 67
sexual dimorphism studies of brain 70, 71

GATA4
bipotential genital ridge development
role 4, 5
testes development role 7, 8, 174
Genital tubercle
anogenital difference 19
differentiation 18, 24, 25

Germ cell cancer
environmental factors 178, 179
genetic screening 194
germ cell development 175–177
gonadectomy
androgen insensitivity syndrome 191
boys with gonadal dysgenesis 190
girls with gonadal dysgenesis 190, 191
overview of decision factors 188, 189
ovotesticular disorders of sex
development 191, 192
imaging 192, 193
markers
epigenetic markers 178, 179
overview 177, 178
semen markers 193
serum markers 180, 193
pathophysiology 173
prospects for study 181, 182
risks in disorders of sex development
age effects 188
disorder type effects 187, 188
gonad localization effects 187, 188
overview 172, 185–187
susceptibility genes 186, 187
self-examination 192
survival 173
Global Rare Diseases Patient Registry and Data Repository 246
Gonad development
bipotential genital ridge development genes
  \( CBX2 \), 4
  \( Emx2 \), 5
  \( GATA4 \), 4, 5
  \( LHx9 \), 4, 5
  \( NR5A1 \), 4
  \( WT1 \), 3, 4
ovary development genes
  \( FOXL2 \), 12, 13
  \( RSPO1 \), 13
  \( WNT4 \), 11, 12
overview 1, 2, 13, 14, 173, 174
testes development genes
  anti-Müllerian hormone 8, 9, 19
  \( ATRX \), 10, 11
  Desert Hedgehog 9, 10
  \( DMRT1 \), 9
  \( FOG2 \), 7, 8
  \( GATA4 \), 7, 8
  mitogen-activated protein kinase 10
  \( NR5A1 \), 7
  \( SOX9 \), 6
  \( SRY \), 5, 6
Gonadectomy, see Germ cell cancer
GrApSIA
  annual meetings 141, 142
  family meetings 142
  formation 139, 140
  goals
    education 141
    links with professionals 141
  overview 140–142
  testimonials
    adolescent concerns 145
    age distribution 143
    denial stage 143, 144
    diagnosis response 143
    GrApSIA role 146, 147
    identity 144
    motherhood 146
    partner relationships 145, 146
    physician-patient relationship 146
    sexual relationships 145
    social setting 146
  HEEADDSSS 133
  Hormone replacement therapy
    androgens 153–156
    estrogen 150–153, 157
  Hydrocortisone replacement therapy, see
    Congenital adrenal hyperplasia
  monitoring 156, 157
  overview 149, 150
  Human chorionic gonadotropin, germ cell cancer marker 193
  Hydrocortisone replacement therapy, see
    Congenital adrenal hyperplasia
  \( 11\beta \)-Hydroxylase deficiency, see also Congenital adrenal hyperplasia
    fertility 96
    steroid measurement 47, 48
    steroidogenesis defect 43
  \( 17\alpha \)-Hydroxylase deficiency
    fertility 93
    steroid measurement 50
    steroidogenesis defect 42, 43
  \( 21 \)-Hydroxylase deficiency, see also Congenital adrenal hyperplasia
    fertility 95
    incidence 284
    steroid measurement 47, 48
    steroidogenesis defect 43
  \( 3\beta \)-Hydroxysteroid dehydrogenase deficiency, see also Congenital adrenal hyperplasia
    fertility 93, 94, 96
    steroid measurement 47, 48
    steroidogenesis defect 43
  \( 17\beta \)-Hydroxysteroid dehydrogenase deficiency
    fertility 94
    gonad imaging 81, 82
    imaging recommendations 79
    steroid measurement 47, 51
  Hypospadias repair
    anesthesia 198–200
    anthropometric considerations 200
    complications 198
    psychosexual considerations 200, 201
    surgical considerations 198
    timing 197–199
  I-DSD Registry 247, 290, 291
  Inter-Act Youth 128
  International Rare Diseases Research Consortium 241, 289
  Intersex Society of North America 101
<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIT</td>
<td>c-KIT as germ cell cancer marker 177 &lt;br&gt;germ cell development role 175 &lt;br&gt;KITLG, germ cell cancer marker 177, 178, 185–187</td>
</tr>
<tr>
<td>Laparoscopy, gonad investigation</td>
<td>77</td>
</tr>
<tr>
<td>Leiden open source variation database</td>
<td>60, 61</td>
</tr>
<tr>
<td>LHX9</td>
<td>bipotential genital ridge development role 4, 5</td>
</tr>
<tr>
<td>IncRNA-seq</td>
<td>60</td>
</tr>
<tr>
<td>Luteinizing hormone receptor, mutations and fertility</td>
<td>92</td>
</tr>
<tr>
<td>17,20-Lyase deficiency</td>
<td>fertility 93 &lt;br&gt;steroid measurement 50 &lt;br&gt;steroidogenesis defect 43</td>
</tr>
<tr>
<td>Magnetic resonance imaging</td>
<td>congenital adrenal hyperplasia 72 &lt;br&gt;genital imaging 84, 85 &lt;br&gt;germ cell cancer 192, 193 &lt;br&gt;gonad imaging 77, 78, 80–84 &lt;br&gt;neuroimaging principles 64, 65 &lt;br&gt;sexual dimorphism studies of brain 70</td>
</tr>
<tr>
<td>Magnetic resonance spectroscopy</td>
<td>neuroimaging principles 67, 68 &lt;br&gt;sexual dimorphism studies of brain 71</td>
</tr>
<tr>
<td>Masculinization programming window</td>
<td>anogenital difference 23 &lt;br&gt;females 22, 23 &lt;br&gt;knockout mouse studies 23–25 &lt;br&gt;males &lt;br&gt;clinical implications 21, 22 &lt;br&gt;overview 29 &lt;br&gt;prospects for study 25</td>
</tr>
<tr>
<td>Masculinizing genital surgery</td>
<td>see Phalloplasty</td>
</tr>
<tr>
<td>Mass spectrometry, steroid measurement</td>
<td>45–47, 61</td>
</tr>
<tr>
<td>Methylation of cytosine sequencing</td>
<td>59, 60</td>
</tr>
<tr>
<td>Microarray</td>
<td>see Phalloplasty</td>
</tr>
<tr>
<td>MicroRNA, germ cell cancer markers</td>
<td>180, 193</td>
</tr>
<tr>
<td>Mitogen-activated protein kinase, testes development role</td>
<td>10</td>
</tr>
<tr>
<td>Müllerian duct, differentiation</td>
<td>19</td>
</tr>
<tr>
<td>National Center for Advancing Translational Sciences</td>
<td>246</td>
</tr>
<tr>
<td>National Center for Rare Diseases</td>
<td>236–238, 241, 242</td>
</tr>
<tr>
<td>Neuroimaging, see Brain, specific techniques</td>
<td></td>
</tr>
<tr>
<td>Next generation sequencing, see Whole exome sequencing, Whole genome sequencing</td>
<td></td>
</tr>
<tr>
<td>NR5A1</td>
<td>bipotential genital ridge development role 4 &lt;br&gt;testes development role 7</td>
</tr>
<tr>
<td>Office of Rare Diseases</td>
<td>240</td>
</tr>
<tr>
<td>Office of Rare Diseases Research</td>
<td>246, 247</td>
</tr>
<tr>
<td>Ovary, development genes</td>
<td>FOXL2 12, 13 &lt;br&gt;RSPOI 13 &lt;br&gt;WNT4 11, 12</td>
</tr>
<tr>
<td>P450 oxidoreductase deficiency</td>
<td>fertility 93 &lt;br&gt;steroid measurement 47, 49 &lt;br&gt;steroidogenesis defect 43</td>
</tr>
<tr>
<td>P450scc, fertility with defects</td>
<td>93</td>
</tr>
<tr>
<td>Peer support, disorders of sex development efficacy studies</td>
<td>102–105</td>
</tr>
<tr>
<td>GrApSIA for androgen insensitivity</td>
<td>syndrome &lt;br&gt;annual meetings 141, 142 &lt;br&gt;family meetings 142 &lt;br&gt;formation 139, 140 &lt;br&gt;goals &lt;br&gt;education 141 &lt;br&gt;links with professionals 141 &lt;br&gt;overview 140–142 &lt;br&gt;testimonials &lt;br&gt;adolescent concerns 145 &lt;br&gt;age distribution 143 &lt;br&gt;denial stage 143, 144 &lt;br&gt;diagnosis response 143 &lt;br&gt;GrApSIA role 146, 147 &lt;br&gt;identity 144 &lt;br&gt;motherhood 146 &lt;br&gt;partner relationships 145, 146 &lt;br&gt;physician-patient relationship 146 &lt;br&gt;sexual relationships 145 &lt;br&gt;social setting 146 &lt;br&gt;historical perspective 100–102 &lt;br&gt;organizations &lt;br&gt;North America 106 &lt;br&gt;outside North America 107 &lt;br&gt;overview 99, 100 &lt;br&gt;prospects 108–110 &lt;br&gt;support group characteristics 105–108 &lt;br&gt;transition to adult care 129</td>
</tr>
</tbody>
</table>
Penis
  development 18, 19, 21
surgery, see Hypospadias repair, Phalloplasty
Phalloplasty
  historical perspective 225
  indications 222, 223
  micropenis
    causes 223
    psychosocial management 228–230
    treatment options 224, 225
  psychosexual outcome 226, 227
  surgical technique 225
Physician-patient relationship
  adolescent with new diagnosis 122, 123
  early and full disclosure of disorder 123, 124
  legal and ethical issues 125, 126
  medical examinations and privacy 121, 122
  multidisciplinary team 132–134
  overview of communication 113, 114
  physician-child-parent triad 114, 115
  secrecy, shame, and stigma management in families 124, 125
  timing of disorder disclosure to child 115, 116
  tools for communication
    children
      5–8 years of age 118, 119
      8–10 years of age 119
    teenagers 120, 121
    toddlers 116–118
  transition to adult care, see Transition to adult care
Positron emission tomography
  neuroimaging principles 65, 66
  sexual dimorphism studies of brain 71
Primordial germ cell
germ cell development 175–177
sex determination 174
Prostate, development 18
clinical trials and orphan drugs
  androgen insensitivity syndrome 245
  congenital adrenal hyperplasia 244, 245
  overview 243, 244
  definition 234–236
  epidemiology 234, 235
  guidelines and best practices 250
  information sources 250
  initiatives 239–242
  patient organizations 250–253
  prevention 247–250
  registries 246, 247, 290, 291
Rare Diseases Act of 2002 240
5α-Reductase deficiency
  gonad imaging 81
  imaging recommendations 79
  steroid measurement 47, 50
RNA sequencing 60
RSPO1, ovary development role 13, 175
Seminal vesicles, development 18
Seminoma, see Germ cell cancer
Sex hormone replacement, see Hormone replacement therapy
Single photon emission computed tomography
  neuroimaging principles 65
  sexual dimorphism studies of brain 71
SOX2, germ cell cancer marker 177, 178
SOX9, testes development role 6, 174
SOX17, germ cell cancer marker 177
SRY
  sex determination 2, 174
  testes development role 5, 6
  transcription factors 174
Stem cell factor, see KITLG
Steroidogenesis, overview 41–45
Steroidogenic acute regulatory protein
  fertility with defects 93
  function 41, 42, 49
Support group, see GrApSIA, Peer support, disorders of sex development
Testes
  development genes
    anti-Müllerian hormone 8, 9, 19
    ATRX 10, 11
    Desert Hedgehog 9, 10
    DMRT1 9
    FOG2 7, 8
    GATA4 7, 8

Subject Index 299
mitogen-activated protein kinase 10
NR5A1 7
SOX9 6
SRY 5, 6
fetal testosterone production 18
Testis-specific enhancer, SOX9 gene 6
Testis-specific protein Y, germ cell cancer expression 178, 185
Testosterone, see also Androgen receptor
fetal production 18
synthesis 43, 44
Transition to adult care
checklist for adolescent preparation 130
continuity 135
effectiveness measures 136
gradual transition 134, 135
interventions 135
medical and surgical needs 129, 131
multidisciplinary team
communications 133, 134
overview 132, 133
service adaptation 134
parent empowering 131, 132
patient education 129
psychological and peer support needs 129
Turner syndrome, fertility 88, 90
Ultrasound
gonad imaging 77, 78, 80
vagina and sex duct imaging 84
Urinary tract infection, prevention with early feminizing surgery 211, 212
Vaginoplasty, see Feminizing genitoplasty
Whole exome sequencing
coverage 55, 56
data sets 56, 57
next generation sequencing
disorders of sex development
applications 58–60
platforms 55
reporting of results 57, 58
whole genome sequencing
comparison 54–56
Whole genome sequencing
next generation sequencing
disorders of sex development
applications 58–60
platforms 55
reporting of results 57, 58
whole exome sequencing
comparison 54–56
WNT4, ovary development role 11, 12, 175
Wolffian duct
differentiation 19
masculinization programming window 20
testosterone effects 18
WT1
bipotential genital ridge development
role 3, 4
sex determination 174